Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
Merck
Medtronic
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,662,404

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,662,404
Title:Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
Abstract: The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of a peptide or polypeptide that generates hydrophilic micro-channels, and a patch comprising dried therapeutically peptide or polypeptide. Particularly, the system of the present invention facilitates transdermal delivery of parathyroid hormone useful for preventing or treating bone disorders.
Inventor(s): Stern; Meir (Rehovot, IL), Levin; Galit (Nordiya, IL)
Assignee: TransPharma Medical Ltd. (Lod, IL)
Application Number:11/582,920
Patent Claims:1. A method for treating a bone disorder or disease comprising: (a) generating a plurality of micro-channels in an area of the skin of a subject; (b) affixing a printed patch to the area of the skin of the subject, the printed patch comprising a non-adhesive liner and a dried pharmaceutical composition comprising a therapeutically effective amount of a parathyroid hormone (PTH) or a fragment thereof that has PTH activity, and wherein the non-adhesive liner is made of a material that is not permeable to the PTH, and thereby treating the bone disorder or disease.

2. The method according to claim 1, wherein the PTH is a human PTH.

3. The method according to claim 2, wherein the human PTH is the fragment human PTH (1-34).

4. The method according to claim 1, wherein the pharmaceutical composition further comprises a stabilizer.

5. The method according to claim 4, wherein the stabilizer is a simple or complex carbohydrate.

6. The method according to claim 5, wherein the simple or complex carbohydrate is selected from the group consisting of mannose, glucose, galactose, raffinose, cellobiose, gentiobiose, sucrose and trehalose.

7. The method according to claim 1, wherein the pharmaceutical composition further comprises an acidic component to yield a pH in the range from about 3 to about 6 in solution before drying.

8. The method according to claim 7, wherein the acidic component is selected from the group consisting of acetic acid, citric acid, and tartaric acid.

9. The method according to claim 8, wherein the pharmaceutical composition comprises hPTH (1-34), acetic acid, and trehalose at pH of about 4.0 in solution before drying.

10. The method according to claim 1, wherein the bone disorder or disease is selected from the group consisting of bone fractures, osteoporosis, arthritis, osteoarthritis, and glucocorticoid osteoporosis.

11. The method according to claim 1, wherein the subject is a human.

12. The method according to claim 1, wherein the subject is a woman.

13. The method according to claim 1, wherein the subject is a postmenopausal woman suffering from osteoporosis.

14. The method according to claim 1, wherein the pharmaceutical composition further comprising an antiresorptive agent.

15. The method according to claim 14, wherein the antiresorptive agent is selected from the group consisting of calcitonin, estrogen, bisphosphonates, fluoride, vitamin D, IGF-1, statins, and selective estrogen receptor modulators (SERMs).

16. The method according to claim 1, further comprising a step of administering a pharmaceutical composition comprising a therapeutically effective amount of an antiresorptive agent before, concurrently, or after affixing the patch.

17. The method according to claim 16, wherein the antiresorptive agent is selected from the group consisting of calcitonin, estrogen, bisphosphonates, fluoride, vitamin D, IGF-1, statins, and selective estrogen receptor modulators (SERMs).

18. The method according to claim 1, wherein the bone disorder is osteoporosis, and the pharmaceutical composition further comprises trehalose as a stabilizer, acetic acid in an amount sufficient to yield a pH in the range from about 3 to about 6 in solution before drying, and vitamin D as an antiresorptive agent.

19. The method according to claim 18, wherein the PTH peptide is human PTH (1-34) and the subject to be treated is a woman.

20. The method according to claim 1, wherein the bone disorder is osteoporosis, and the pharmaceutical composition further comprises trehalose as a stabilizer, and acetic acid in an amount sufficient to yield a pH in the range from about 3 to about 6 in solution before drying.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel152574Oct 31, 2002

Details for Patent 7,662,404

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial TransPharma Medical Ltd. (Lod, IL) 2022-10-31 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial TransPharma Medical Ltd. (Lod, IL) 2022-10-31 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial TransPharma Medical Ltd. (Lod, IL) 2022-10-31 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial TransPharma Medical Ltd. (Lod, IL) 2022-10-31 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,662,404

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Moodys
Medtronic
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.